Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions

News provided by

Jan 25, 2024, 07:35 ET

New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State

MADISON, Wis., Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife^® S7™ System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients.

"The Providence Swedish Radiosurgery Center began using their first CyberKnife System more than 10 years ago. Since then, we've built a valuable partnership based on our mutual goal to transform the cancer patient experience with technologies that improve patient comfort during treatment and extend both survivorship and quality of life post-treatment," said Suzanne Winter, President and CEO of Accuray. "I couldn't be prouder that the Providence Swedish Radiosurgery team is continuing to invest in Accuray technologies. It signifies their confidence in our company, our people and our products."

The CyberKnife S7 System is a non-invasive radiation therapy device that was built from the ground-up to provide clinicians with the speed they need for operational efficiency without sacrificing the precision and accuracy required for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The system uses artificial intelligence (AI) to track and automatically adapt for tumor or patient movement during treatment, delivering the radiation dose directly to the target with sub-millimeter precision - in as little as 15 minutes.

"At Providence Swedish Radiosurgery Center, we recognize that treatment decisions significantly impact patients' immediate health and long term quality of life. Our top priority is to provide excellent care for each person who walks through our door, leveraging the latest innovations in radiation therapy technologies and techniques to improve patient outcomes," said Dr. Christopher Loiselle, Executive Medical Director, Providence Swedish Radiosurgery Center and President of the Tumor Institute Radiation Oncology Group. "We have had a successful experience with the CyberKnife System and a positive relationship with the Accuray team. We purchased the CyberKnife S7 device because we are confident the system will further our ability to meet our patient-centered treatment goals."

The Providence Swedish Radiosurgery Center team has made significant contributions to the field of radiation medicine including leading the first large, multi-center clinical trial with long-term follow-up evaluating the use of SBRT in prostate cancer delivered by the CyberKnife System. They also are actively involved in research assessing the use of SBRT to treat tumors in other areas of the body and radiosurgery in the treatment of cancer and medical conditions in the brain.

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the company's goals and partnerships with customers; expectations regarding future purchases by customers; the ability of the company's products to meet the goals of its customers; patient experiences and patient outcomes. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 7, 2023, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
[email protected]

SOURCE Accuray Incorporated